COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended							3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 07, 2019	Aug. 27, 2018	Dec. 31, 2022	Jul. 31, 2022	Apr. 30, 2022	May 31, 2020	Apr. 30, 2020	Oct. 31, 2019	May 31, 2019	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Apr. 04, 2022
Loss Contingencies [Line Items]
Proceeds from royalties received													$ 50,250
Annual royalty obligation													$ 4,020
Options to acquire shares					144,191
Weighted exercise price					$ 10.71
Warrants to purchase shares					4,424
Exercise price					$ 7.32
Expiration date					Apr. 22, 2031
Cash consideration				$ 10,000,000.0
Number of shares				486,145
Net income										$ (38,447)		$ (12,512)	$ (76,876)	$ (39,693)
Common Stock [Member]
Loss Contingencies [Line Items]
Warrants to purchase shares					12,301
Exercise price					$ 12.05
Expiration date					Aug. 10, 2030
Number of shares isssued											26,143
Precision Healing Inc [Member]
Loss Contingencies [Line Items]
Cash consideration					$ 125,966
Payments receive					$ 10,000,000.0
Precision Healing [Member]
Loss Contingencies [Line Items]
Payments receive							$ 10,000,000.0
2009 [Member] | Resorbable Bone Hemostat [Member]
Loss Contingencies [Line Items]
Royalty percentage													2.00%
Rochal [Member]
Loss Contingencies [Line Items]
Payment of cash						$ 500,000
Accredited Investors [Member]
Loss Contingencies [Line Items]
Issuance of shares					165,738
Nonaccredited Investors [Member]
Loss Contingencies [Line Items]
Share price																$ 30.75
Minimum [Member]
Loss Contingencies [Line Items]
Proceeds from royalties received													$ 201,000
Minimum [Member] | 2009 [Member] | Resorbable Bone Hemostat [Member]
Loss Contingencies [Line Items]
Payments for royalties													201,000
Precision Healing [Member]
Loss Contingencies [Line Items]
Payment in cash					$ 600,000
Share price					$ 27.13		$ 27.13
Wound Care Solutions Limited [Member]
Loss Contingencies [Line Items]
Net income			$ 242,000		$ 220,000				$ 200,000
Wound Care Solutions Limited [Member] | 2021 Through 2024 [Member]
Loss Contingencies [Line Items]
Net income, percentage									10.00%
Cost of Sales [Member]
Loss Contingencies [Line Items]
Royalty expense										$ 548,430		$ 443,733	1,069,244	812,966
Annual royalty obligation													16,080
Sub License Agreement [Member]
Loss Contingencies [Line Items]
License agreement and royalties description		In August 2018, the Company entered an exclusive, world-wide sublicense agreement (the “Sublicense Agreement”) with CGI Cellerate RX, LLC (“CGI Cellerate RX”) to distribute CellerateRX Surgical Activated Collagen (Powder and Gel) (“CellerateRX Surgical”) and HYCOL Hydrolyzed Collagen (Powder and Gel) (“HYCOL”) products into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company pays royalties of 3-5% of annual collected net sales of CellerateRX Surgical and HYCOL. As amended in January 2021, the term of the sublicense extends through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the initial expiration date, CGI Cellerate RX will have the right to terminate the Sublicense Agreement upon written notice.
BIAKOS License Agreement [Member]
Loss Contingencies [Line Items]
Royalty expense													65,000	$ 60,000
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member]
Loss Contingencies [Line Items]
Increase of royalties payable													10,000
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage	2.00%
Payments for royalties															$ 120,000
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage	4.00%
Payments for royalties													150,000
BIAKOS Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for additional royalties													$ 1,000,000
ABF License Agreement [Member]
Loss Contingencies [Line Items]
Royalty annual minimum percentage													10.00%
ABF License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage								2.00%
Payments for royalties								$ 50,000
ABF License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage								4.00%
Payments for royalties													$ 75,000
Payment for additional royalties													$ 500,000
Debrider License Agreement [Member]
Loss Contingencies [Line Items]
Royalty annual minimum percentage													10.00%
Payment of cash						$ 1,000,000
Debrider License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage						2.00%
Payments for royalties						$ 100,000
Debrider License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage						4.00%
Payments for royalties													$ 150,000
Payment for additional royalties													$ 1,000,000
Royalty Agreement [Member] | 2009 [Member] | Resorbable Bone Hemostat [Member]
Loss Contingencies [Line Items]
Royalty annual minimum percentage													8.00%
Purchase Agreement [Member]
Loss Contingencies [Line Items]
Acquisition consideration transferred				$ 7,600,000
Cash				$ 1,600,000
Issuance of common stock for purchase of assets				291,686
Number of shares isssued				94,798